title: [Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].
abstract: BACKGROUND
  Chronic myeloid leukemia is a myeloproliferative disease characterized by the Philadelphia chromosome and with this, the chimeric protein BCR-ABL. The first-line treatment is imatinib, a tyrosine kinase inhibitor, that has showed good results, but with a significant percentage of treatment failure. This failure has led to second-generation tyrosine kinase inhibitors as second-line treatment such as dasatinib.
  
  
  OBJECTIVE
  The objective of the study was to evaluate the efficacy of dasatinib as second-line treatment.
  
  
  METHODS
  Observational, longitudinal, and retrospective study. Patients with diagnosis of chronic myeloid leukemia that presented failure to first-line treatment were included in the present study; the hematologic response was evaluated at 3, 6, and 12 months, and molecular response at 12 months of follow-up after dasatinib treatment was started.
  
  
  RESULTS
  Of a total of 14 patients that were included in the study, a response in the white cell count of 84.6% with a mean response at 4.7 months of follow-up was observed; also 84.6% platelet response with a mean response at 4.7 months of follow-up. Molecular response was also evaluated at a 12-month follow-up, achieving a 50% response with a mean response at 11.08 months of follow-up. A survival rate of 80% at a 12-month follow-up was observed.
  
  
  CONCLUSIONS
  The use of dasatinib as a second-line treatment is effective in achieving a sustained hematologic response of 84.6% and a molecular response in 50%, also finding a hematologic response without achieving a total molecular response.
authors.affiliation: Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
authors.forename: Juan Enrique
authors.initials: JE
authors.lastname: Santos-Macías
authors.affiliation: Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
authors.forename: Enrique
authors.initials: E
authors.lastname: Baez de la Fuente
authors.affiliation: Departamento de Hematología, UMAE No 25, Monterrey, N.L., México.
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Salas-Delgado
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069439:Dasatinib / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069439:Dasatinib